Our track record
Since 2019, we have completed 60 biotechnology strategy reviews, undertaken 20+ sell-side transactions & 30+ buy-side projects.
We support a broad set of transactions, including:
- Management-led buyouts
- Disposals (assets and stock)
- Specialist Commercial Due Diligence (CDD)
- We have a proprietary database of sellers globally, covering manufacturers, distributors and hybrid resellers.
Pivotal Scientific represented Nordic MUBio in their acquisition of Scicons
Pivotal Scientific represented Absolute Antibody in their acquisition by LSBio
Pivotal Scientific represented Dianova GmbH in their acquisition to Calibre Scientific